论文部分内容阅读
为探讨肿瘤坏死因子。在肝炎后肝硬化并发自发性细菌性腹膜炎（SBP）中的变化及临床意义，采用双抗体夹心法酶联免疫吸附试验，检测肝硬化腹水患者、肝硬化并发SBP患者及癌性腹水患者血清或腹水中肿瘤坏死因子α水平。结果显示：肝硬化并发SBP及癌性腹水患者肿瘤坏死因子α水平明显升高，与正常对照组比较均有明显差异（P＜0．05）；肝硬化并发SBP患者腹水中肿瘤坏死因子α较肝硬化腹水患者明显升高（P＜0．05）。经抗生素治疗后，肝硬化并发SBP患者血清或腹水中肿瘤坏死因子α显著下降（P＜0．05）。提示：检测血清或腹水中肿瘤坏死因子α水平可反映机体的感染状况、预测治疗的效果与预后。
To explore tumor necrosis factor. In patients with post-hepatitis cirrhosis complicated with spontaneous bacterial peritonitis (SBP) and its clinical significance, the use of double antibody sandwich enzyme-linked immunosorbent assay in patients with cirrhosis and ascites, patients with cirrhosis and SBP ascites and ascitic fluid in patients with serum or Ascites tumor necrosis factor alpha levels. The results showed that the level of tumor necrosis factor-α in cirrhotic patients with SBP and cancerous ascites was significantly higher than that in the normal control group (P <0.05). The tumor necrosis factor-α Patients with cirrhosis were significantly higher (P <0.05). After antibiotic treatment, serum or ascites tumor necrosis factor-alpha in cirrhotic patients with SBP was significantly decreased (P <0.05). Tip: Detection of serum or ascites tumor necrosis factor α levels can reflect the body’s infection status, predict the effect of treatment and prognosis.